Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
115.53
-3.01 (-2.54%)
Mar 31, 2025, 9:53 AM EDT - Market open
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Axsome Therapeutics stock have an average target of 168.93, with a low estimate of 105 and a high estimate of 216. The average target predicts an increase of 46.23% from the current stock price of 115.53.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Axsome Therapeutics stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 7 | 7 | 6 | 6 |
| Buy | 6 | 6 | 7 | 7 | 8 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $212 → $216 | Buy | Maintains | $212 → $216 | +86.97% | Mar 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $200 | Strong Buy | Reiterates | $200 | +73.12% | Mar 6, 2025 |
| Needham | Needham | Strong Buy Reiterates $153 | Strong Buy | Reiterates | $153 | +32.44% | Mar 3, 2025 |
| Baird | Baird | Buy Maintains $132 → $160 | Buy | Maintains | $132 → $160 | +38.50% | Mar 3, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $125 → $190 | Buy | Maintains | $125 → $190 | +64.47% | Feb 27, 2025 |
Financial Forecast
Revenue This Year
636.61M
from 385.69M
Increased by 65.06%
Revenue Next Year
1.04B
from 636.61M
Increased by 63.84%
EPS This Year
-3.30
from -5.99
EPS Next Year
2.19
from -3.30
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 720.8M | 1.3B | 2.1B | ||
| Avg | 636.6M | 1.0B | 1.6B | ||
| Low | 547.8M | 764.6M | 1.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 86.9% | 108.9% | 98.7% | ||
| Avg | 65.1% | 63.8% | 54.4% | ||
| Low | 42.0% | 20.1% | 18.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.76 | 7.90 | 17.25 | ||
| Avg | -3.30 | 2.19 | 10.02 | ||
| Low | -4.61 | -3.05 | -0.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 686.6% | ||
| Avg | - | - | 356.8% | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.